Zobrazeno 1 - 10
of 42
pro vyhledávání: '"G. A. Tollefson"'
Publikováno v:
BMC Medical Genomics, Vol 17, Iss 1, Pp 1-11 (2024)
Abstract Background Globally, preterm birth remains the leading cause of death in children younger than 5 years old. Spontaneous preterm birth is comprised of two events that may or may not occur simultaneously: preterm labor and preterm prelabor rup
Externí odkaz:
https://doaj.org/article/a6551ad3c47d4d7f96fd5174ad964022
Autor:
G. D. Tollefson, Michael Poyurovsky, Haggai Hermesh, Hanan Munitz, Abraham Weizman, Pnina Dorfman-Etrog
Publikováno v:
International Clinical Psychopharmacology. 15:169-173
Some studies suggest that obsessive-compulsive symptoms may be common (7.8-46%) in schizophrenic patients and seem to be poorly responsive to drug therapy. Conventional neuroleptics are of limited value, but adjunctive anti-obsessive agents (clomipra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a35b1c1b7db75f1887001cfe43070fb7
https://doi.org/10.1097/00004850-200015030-00006
https://doi.org/10.1097/00004850-200015030-00006
Publikováno v:
The Journal of clinical psychiatry. 62(2)
Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::51cfc112225d236538ab275b4e19e038
https://pubmed.ncbi.nlm.nih.gov/11247108
https://pubmed.ncbi.nlm.nih.gov/11247108
Autor:
M R, Dossenbach, P, Kratky, M, Schneidman, S L, Grundy, S, Metcalfe, G D, Tollefson, R H, Belmaker
Publikováno v:
The Journal of clinical psychiatry. 62
This multicenter, open-label study evaluated the efficacy and safety of olanzapine in patients with schizophrenia who had been nonresponsive or intolerant to a course of risperidone (mean duration of risperidone treatment = 46.3 days).A total of 34 p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a952e42ca1a0bb019947c7d4223c3bef
https://pubmed.ncbi.nlm.nih.gov/11232749
https://pubmed.ncbi.nlm.nih.gov/11232749
Autor:
S E, Purdon, B D, Jones, E, Stip, A, Labelle, D, Addington, S R, David, A, Breier, G D, Tollefson
Publikováno v:
Archives of general psychiatry. 57(3)
The purpose of this investigation was to test the efficacy of novel antipsychotic medications in the treatment of cognitive impairment in early phase schizophrenia.Sixty-five patients in this multicenter double-blind study were randomly assigned to o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e386ef7b60d5bed9ac78e9aa3989fb2b
https://pubmed.ncbi.nlm.nih.gov/12044210
https://pubmed.ncbi.nlm.nih.gov/12044210
Publikováno v:
Journal of clinical psychopharmacology. 19(5)
The abrupt appearance of clozapine discontinuation symptoms represents a particularly unique situation that has not been characterized in a double-blind, placebo-controlled trial. A randomized, double-blind comparison of placebo (N = 53) and olanzapi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ff82ad3e3102c936b2f4378d5a82365b
https://pubmed.ncbi.nlm.nih.gov/10505585
https://pubmed.ncbi.nlm.nih.gov/10505585
Autor:
M, Tohen, T M, Sanger, S L, McElroy, G D, Tollefson, K N, Chengappa, D G, Daniel, F, Petty, F, Centorrino, R, Wang, S L, Grundy, M G, Greaney, T G, Jacobs, S R, David, V, Toma
Publikováno v:
The American journal of psychiatry. 156(5)
The primary intent of this study was to compare the efficacy and safety of olanzapine and placebo in the treatment of acute mania.The design involved a random-assignment, double-blind, placebo-controlled parallel group study of 3 weeks' duration. Aft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d60a1916d6a58c83637cf54a635f8b5b
https://pubmed.ncbi.nlm.nih.gov/10327902
https://pubmed.ncbi.nlm.nih.gov/10327902
Autor:
G D, Tollefson, A J, Kuntz
Publikováno v:
The British journal of psychiatry. Supplement. (37)
Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments. Clinical investigations employing olanzapine have demonstrated a number of potential therapeutic advant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8d924dc43eaa6e15157d123795b055cf
https://pubmed.ncbi.nlm.nih.gov/10616618
https://pubmed.ncbi.nlm.nih.gov/10616618
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Autor:
G D, Tollefson, S W, Andersen
Publikováno v:
The Journal of clinical psychiatry. 60
The main objective in the treatment of schizophrenia should be to optimize individual patient functioning and quality of life. Little is known about the possible relationship of concurrent mood symptoms and quality of life. We hypothesized that the q
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bb688f6747b52ba3862eca3f5cb892a4
https://pubmed.ncbi.nlm.nih.gov/10192404
https://pubmed.ncbi.nlm.nih.gov/10192404
Autor:
D, Michelson, R B, Lydiard, M H, Pollack, R N, Tamura, S L, Hoog, R, Tepner, M A, Demitrack, G D, Tollefson
Publikováno v:
The American journal of psychiatry. 155(11)
Although panic attacks account for only a portion of the morbidity of panic disorder and panic attack frequency assessments are unreliable, studies of drug efficacy in panic disorder have generally used reduction in panic attack frequency as the prim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9400baae01cd8917e5b418320b92273f
https://pubmed.ncbi.nlm.nih.gov/9812120
https://pubmed.ncbi.nlm.nih.gov/9812120